Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Incyte Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Incyte Corporation - Product Pipeline Review - 2014', provides an overview of the Incyte Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Incyte Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Incyte Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Incyte Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Incyte Corporation's pipeline products Reasons to buy - Evaluate Incyte Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Incyte Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Incyte Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Incyte Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Incyte Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Incyte Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Incyte Corporation Snapshot 5 Incyte Corporation Overview 5 Key Information 5 Key Facts 5 Incyte Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Incyte Corporation - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Incyte Corporation - Pipeline Products Glance 14 Incyte Corporation - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Incyte Corporation - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Incyte Corporation - Drug Profiles 17 ruxolitinib phosphate 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 INCB-047986 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 INCB-24360 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 INCB-39110 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Drug for Chronic Inflammatory Condition 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Drugs for Cancer 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 INCB-040093 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 INCB-050465 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules for Inflammation 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Incyte Corporation - Pipeline Analysis 31 Incyte Corporation - Pipeline Products by Target 31 Incyte Corporation - Pipeline Products by Route of Administration 32 Incyte Corporation - Pipeline Products by Molecule Type 33 Incyte Corporation - Pipeline Products by Mechanism of Action 34 Incyte Corporation - Recent Pipeline Updates 35 Incyte Corporation - Dormant Projects 46 Incyte Corporation - Discontinued Pipeline Products 48 Discontinued Pipeline Product Profiles 48 aderbasib 48 INCB-15050 48 INCB-8696 48 INCB-9471 48 Incyte Corporation - Company Statement 49 Incyte Corporation - Locations And Subsidiaries 52 Head Office 52 Other Locations & Subsidiaries 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables Incyte Corporation, Key Information 5 Incyte Corporation, Key Facts 5 Incyte Corporation - Pipeline by Indication, 2014 7 Incyte Corporation - Pipeline by Stage of Development, 2014 10 Incyte Corporation - Monotherapy Products in Pipeline, 2014 11 Incyte Corporation - Out-Licensed Products in Pipeline, 2014 12 Incyte Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Incyte Corporation - Phase III, 2014 14 Incyte Corporation - Phase II, 2014 15 Incyte Corporation - Phase I, 2014 16 Incyte Corporation - Pipeline by Target, 2014 31 Incyte Corporation - Pipeline by Route of Administration, 2014 32 Incyte Corporation - Pipeline by Molecule Type, 2014 33 Incyte Corporation - Pipeline Products by Mechanism of Action, 2014 34 Incyte Corporation - Recent Pipeline Updates, 2014 35 Incyte Corporation - Dormant Developmental Projects,2014 46 Incyte Corporation - Discontinued Pipeline Products, 2014 48 Incyte Corporation, Subsidiaries 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.